Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and β-lactams

被引:13
作者
Gradelski, E [1 ]
Valera, L [1 ]
Kolek, B [1 ]
Bonner, D [1 ]
Fung-Tomc, J [1 ]
机构
[1] Bristol Myers Squibb Co, Dept Microbiol, Wallingford, CT 06492 USA
关键词
BMS-284756; quinolones; killing;
D O I
10.1016/S0924-8579(01)00343-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The primary bactericidal classes used therapeutically as single agents, are the quinolones and the cell-wall active agents. In this study, their rates of killing were compared. The des-fluoro(6) quinolone BMS-284756 (T-3811ME), fluoroquinolones (trovafloxacin, levofloxacin) and cell wall-active agents (beta -lactams, vancomycin) were evaluated against Enterobacteriaceae, Staphylococcus aureus, streptococci, and Enterococcus faecalis. Time-kill analysis was done at 10 x the MIC, using Mueller-Hinton broth (supplemented with 7% lysed horse blood for Streptococcus pneumoniae and the viridans streptococci), or Brain Heart Infusion broth for beta -haemolytic streptococci. Using a 3-log(10) decrease in viable count as an index of bactericidal activity, BMS-284756 and the fluoroquinolones killed Enterobacteriaceae rapidly, requiring < 2 h versus greater than or equal to 6 h for beta -lactams. The staphylococcal cell counts generally decreased more rapidly with quinolone exposure. compared with those treated with vancomycin or the beta -lactams. The antimicrobial agents killed streptococci and enterococci more slowly, requiring > 6 It to decrease the viable count by 99.9%. In summary, BMS-284756 killing rates are similar to those of recent fluoroquinolones and are bacterial group-dependent. Overall, the quinolones are more rapidly bactericidal than vancomycin and the beta -lactam antibiotics. (C) 2001 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 15 条
  • [1] [Anonymous], 1999, M26A NAT COMM CLIN L
  • [2] Bactericidal properties of moxifloxacin and post-antibiotic effect
    Boswell, FJ
    Andrews, JM
    Wise, R
    Dalhoff, A
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 : 43 - 49
  • [3] EFFICACY OF TEMAFLOXACIN IN EXPERIMENTAL STREPTOCOCCUS-ADJACENS ENDOCARDITIS AND AUTORADIOGRAPHIC DIFFUSION PATTERN OF [C-14] TEMAFLOXACIN IN CARDIAC VEGETATIONS
    CREMIEUX, AC
    SALEHMGHIR, A
    VALLOIS, JM
    MAZIERE, B
    MUFFATJOLY, M
    DEVINE, C
    BOUVET, A
    POCIDALO, JJ
    CARBON, C
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (10) : 2216 - 2221
  • [4] DEBBIA E, 1987, CHEMIOTERAPIA, V4, P319
  • [5] PARENTERAL SPARFLOXACIN COMPARED WITH CEFTRIAXONE IN TREATMENT OF EXPERIMENTAL ENDOCARDITIS DUE TO PENICILLIN-SUSCEPTIBLE AND PENICILLIN-RESISTANT STREPTOCOCCI
    ENTENZA, JM
    BLATTER, M
    GLAUSER, MP
    MOREILLON, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) : 2683 - 2688
  • [6] Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis
    Entenza, JM
    Vouillamoz, J
    Glauser, MP
    Moreillon, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (01) : 77 - 84
  • [7] Comparative killing rates of fluoroquinolones and cell wall-active agents
    Fung-Tomc, JC
    Gradelski, E
    Valera, L
    Kolek, B
    Bonner, DP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (05) : 1377 - 1380
  • [8] Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
    Fung-Tomc, JC
    Minassian, B
    Kolek, B
    Huczko, E
    Aleksunes, L
    Stickle, T
    Washo, T
    Gradelski, E
    Valera, L
    Bonner, DP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) : 3351 - 3356
  • [9] Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents
    Hoellman, DB
    Lin, GR
    Jacobs, MR
    Appelbaum, PC
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (05) : 645 - 649
  • [10] Johnson C.C., 1996, ANTIBIOTIC LAB MED, V4th, P813